BioNTech SE
BioNTech SE (BNTX): 126 pipeline candidates · 12 upcoming catalysts · ~12 mo cash runway · 75 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
11.7 months
D/E 0.14 · 0% dilution
Lead: Phase 3
126 candidates
12 upcoming, next in ~35d
0 buys · 1 sell (180d)
A transparent, data-derived signal for BioNTech SEacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$23.3B
Cash
$7.7B
Quarterly Burn
$2.6B
Runway
11.7 mo
Revenue
$2.9B
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (126 candidates)
| Drug | Phase |
|---|---|
| 5-FU | Phase 1 |
| Abiraterone | Phase 1 |
| alk-inhibitor or ret-inhibitor | Phase 1 |
| anti-B7-H3 antibody conjugated to topoisomerase I inhibitor | Phase 1 |
| anti-HER3 antibody conjugated to topoisomerase I inhibitor | Phase 1 |
| Autogene cevumeran | Phase 2 |
| biological/vaccine | Phase 3 |
| bIRV | Phase 2 |
| bispecific antibody for pd-l1 | Phase 1 |
| Bispecific antibody for PD-L1 and VEGF-A | Phase 1 |
Showing 10 of 126 candidates. Sign up for full pipeline.
Upcoming Catalysts (12)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
271
Total value held
$3.68B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 5,709,240 | $507.4M |
| primecap management co/ca/ | 3,793,711 | $337.2M |
| flossbach von storch se | 3,680,315 | $327.1M |
| dodge & cox | 3,676,791 | $326.8M |
| bnp paribas financial markets | 1,651,959 | $148.3M |
| blackrock, inc. | 1,658,153 | $147.4M |
| citadel advisors llc | 1,540,682 | $136.9M |
| bank of america corp /de/ | 903,029 | $80.3M |
| gsk plc | 889,824 | $79.1M |
| baillie gifford & co | 882,572 | $78.4M |
Showing top 10 of 271 institutional holders of BioNTech SE. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in BioNTech SE's pipeline?
BioNTech SE (BNTX) has 126 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is BioNTech SE's lead drug candidate?
BioNTech SE's most advanced tracked candidate is 5-FU (Phase 1) for Malignant Solid Tumor.
What is BioNTech SE's next catalyst?
BioNTech SE's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A MASTER PHASE 1/2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VARIANT" — expected July 23, 2026.
What is BioNTech SE's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, BioNTech SE has approximately 11.7 months of cash runway.
What is BioNTech SE's market capitalization?
BioNTech SE's market capitalization is approximately $23.3B.
Get the full picture on BioNTech SE
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.